Spots Global Cancer Trial Database for pharmacodynamics
Every month we try and update this database with for pharmacodynamics cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer | NCT00504790 | Cancer | GSK923295 | 18 Years - | GlaxoSmithKline | |
| A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer | NCT01220999 | Colorectal Neop... | CS-1008 | 18 Years - | Ludwig Institute for Cancer Research | |
| Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data | NCT00341939 | Prostate Cancer Breast Cancer Cutaneous T-Cel... Lung Cancer Melanoma | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) | NCT04882917 | Advanced Solid ... | M4076 | 18 Years - | EMD Serono | |
| Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer | NCT00504790 | Cancer | GSK923295 | 18 Years - | GlaxoSmithKline | |
| Effect of Metformin on Breast Cancer Metabolism | NCT01266486 | Breast Cancer | Metformin | 18 Years - | Oxford University Hospitals NHS Trust | |
| A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors | NCT05536141 | Clear Cell Rena... Solid Tumors | AB521 | 18 Years - | Arcus Biosciences, Inc. | |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | NCT01851369 | Lymphomas Solid Tumors NSCLC Metastatic Colo... Granulosa Cell ... | TRC102 CT scan Lomotil Prochlorperazin... Metoclopramide 5-HT3 antagonis... Aprepitant Biopsy | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Broccoli Sprout Intervention in Qidong, P.R. China | NCT01437501 | Environmental C... | Broccoli Sprout... placebo beverag... | 21 Years - 65 Years | Johns Hopkins Bloomberg School of Public Health | |
| A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | NCT02801578 | Chronic Lymphoc... | Ibrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | NCT02324998 | Prostate Cancer | Olaparib Degarelix | 18 Years - 73 Years | Cambridge University Hospitals NHS Foundation Trust | |
| A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients | NCT00001449 | Neoplasms | gemcitabine fluorodeoxyurid... leucovorin | - | National Institutes of Health Clinical Center (CC) | |
| Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer | NCT00069160 | Lung Neoplasms Ovarian Neoplas... Cervix Neoplasm... Renal Neoplasms | docetaxel tariquidar 99mTc-sestamibi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients | NCT00055380 | Cancer | Oral cytobrushi... | - | National Institutes of Health Clinical Center (CC) | |
| Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer | NCT02454673 | Gastric Cancer Effects of Chem... Surgery | 18 Years - 85 Years | Clinica Universidad de Navarra, Universidad de Navarra | ||
| Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors | NCT02423057 | Neoplasms Solid Tumors | TdCyd | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas | NCT03030417 | Solid Tumors Lymphoma | LMP744 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | NCT02049541 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas | NCT01794104 | Neoplasm Lymphoma | LMP400 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan | NCT00507143 | Colorectal Neop... Secondary | irinotecan | 18 Years - | National Cancer Center, Korea | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | NCT05066165 | Acute Myeloid L... | Arm 1: NTLA-500... Arm 2: NTLA-500... | 18 Years - | Intellia Therapeutics | |
| Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer | NCT00071058 | Adrenal Cortex ... | XR9576 (Tariqui... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | NCT02049541 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | NCT01391962 | Sarcoma, Alveol... | Cediranib Sunitinib | 16 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | NCT02619253 | Renal Cell Carc... Urinary Bladder... | Pembrolizumab Vorinostat | 18 Years - | Indiana University | |
| A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | NCT00722293 | Neoplasms, Brea... | Doxorubicin Pazopanib (GW78... Epirubicin | 18 Years - | GlaxoSmithKline | |
| Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | NCT04446351 | Neoplasms | GSK6097608 Dostarlimab Cobolimab Belrestotug | 18 Years - | GlaxoSmithKline | |
| A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | NCT01938443 | Cancer Neoplasms | GSK2256098 Trametinib | 18 Years - | GlaxoSmithKline | |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | NCT01681368 | Epithelial Ovar... Peritoneal Neop... Fallopian Tube ... | Birinapant (TL3... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of TAS-116 in Patients With Solid Tumors | NCT02965885 | Advanced Solid ... | TAS-116 | 18 Years - | Taiho Oncology, Inc. | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Trial of TAS-114 in Combination With S-1 | NCT02454062 | Advanced Solid ... | TAS-114 S-1 | 18 Years - | Taiho Oncology, Inc. | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | NCT01938443 | Cancer Neoplasms | GSK2256098 Trametinib | 18 Years - | GlaxoSmithKline | |
| Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors | NCT02630251 | Cancer Neoplasms | GSK2820151 | 18 Years - | GlaxoSmithKline | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Sample Collection and Tracking for the Developmental Therapeutics Clinic | NCT03269578 | Neoplasms Lymphoma | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms | NCT00666926 | Head and Neck N... Prostatic Neopl... Pancreatic Neop... | PF00562271 PF00562271 PF00562271 PF00562271 | 18 Years - | Verastem, Inc. | |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | NCT01851369 | Lymphomas Solid Tumors NSCLC Metastatic Colo... Granulosa Cell ... | TRC102 CT scan Lomotil Prochlorperazin... Metoclopramide 5-HT3 antagonis... Aprepitant Biopsy | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade | NCT00129207 | Tumors | bortezomib | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | NCT01391962 | Sarcoma, Alveol... | Cediranib Sunitinib | 16 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients | NCT00055380 | Cancer | Oral cytobrushi... | - | National Institutes of Health Clinical Center (CC) | |
| Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | NCT02244632 | Colorectal Neop... | Modufolin (arfo... Fluorouracil Oxaliplatin Irinotecan Bevacizumab | 18 Years - | Isofol Medical AB | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas | NCT01794104 | Neoplasm Lymphoma | LMP400 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis | NCT01441089 | Prostate Cancer Breast Cancer Lung Cancer Ovarian Cancer Lymphoma | 3 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | NCT03410927 | Advanced Solid ... Advanced Solid ... | TAS0728 | 18 Years - | Taiho Oncology, Inc. | |
| Phase II ABT-888 With Cyclophosphamide | NCT01306032 | Ovarian Cancer Primary Periton... Serous Carcinom... Triple-Negative... Fallopian Tube ... | ABT-888 Cyclophosphamid... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors | NCT02423057 | Neoplasms Solid Tumors | TdCyd | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Broccoli Sprout Intervention in Qidong, P.R. China | NCT01437501 | Environmental C... | Broccoli Sprout... placebo beverag... | 21 Years - 65 Years | Johns Hopkins Bloomberg School of Public Health | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms | NCT00666926 | Head and Neck N... Prostatic Neopl... Pancreatic Neop... | PF00562271 PF00562271 PF00562271 PF00562271 | 18 Years - | Verastem, Inc. | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer | NCT00071058 | Adrenal Cortex ... | XR9576 (Tariqui... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| Pharmacotherapy Personalization of Cancer Patients | NCT04866498 | Head and Neck N... Oncologic Patie... | Infusion Intrav... | 18 Years - | Poznan University of Medical Sciences | |
| Broccoli Sprout Intervention in Qidong, P.R. China | NCT01437501 | Environmental C... | Broccoli Sprout... placebo beverag... | 21 Years - 65 Years | Johns Hopkins Bloomberg School of Public Health | |
| Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data | NCT00341939 | Prostate Cancer Breast Cancer Cutaneous T-Cel... Lung Cancer Melanoma | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | NCT03027388 | Astrocytoma, Gr... Glioblastoma Mu... Giant Cell Glio... Glioma Oligodendroglio... | LB-100 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma | NCT00221325 | Central Nervous... Intraocular Lym... | Intraventricula... | 18 Years - | University of California, San Francisco | |
| Effect of Metformin on Breast Cancer Metabolism | NCT01266486 | Breast Cancer | Metformin | 18 Years - | Oxford University Hospitals NHS Trust | |
| Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan | NCT00507143 | Colorectal Neop... Secondary | irinotecan | 18 Years - | National Cancer Center, Korea | |
| A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer | NCT00535522 | Cancer | TAK-285 Dose Es... TAK-285 Recomme... | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors | NCT04812509 | Bone Metastases | MW032 Xgeva | 18 Years - | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | NCT00722293 | Neoplasms, Brea... | Doxorubicin Pazopanib (GW78... Epirubicin | 18 Years - | GlaxoSmithKline | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| Evaluation of Safety and Efficacy of Estetrol in Healthy Men | NCT02718378 | Prostatic Neopl... | estetrol placebo | 40 Years - 70 Years | Pantarhei Oncology B.V. | |
| A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer | NCT00535522 | Cancer | TAK-285 Dose Es... TAK-285 Recomme... | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer | NCT05277766 | Peritoneal Carc... Peritoneal Meta... Colorectal Canc... Small Bowel Can... Appendix Cancer Gastric Cancer Pancreatic Canc... Bile Duct Cance... | PIPAC with Nal-... | 18 Years - | University Hospital, Ghent | |
| Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | NCT02324998 | Prostate Cancer | Olaparib Degarelix | 18 Years - 73 Years | Cambridge University Hospitals NHS Foundation Trust | |
| Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis | NCT01441089 | Prostate Cancer Breast Cancer Lung Cancer Ovarian Cancer Lymphoma | 3 Years - | National Institutes of Health Clinical Center (CC) | ||
| Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma | NCT00520533 | Renal Cell Carc... | Chimeric monocl... Sunitinib malat... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors | NCT05536141 | Clear Cell Rena... Solid Tumors | AB521 | 18 Years - | Arcus Biosciences, Inc. | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects | NCT02798978 | Cancer Neoplasms | GSK1795091 Placebo | 18 Years - 50 Years | GlaxoSmithKline | |
| A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma | NCT00221325 | Central Nervous... Intraocular Lym... | Intraventricula... | 18 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
